Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -22.17% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -26.62%. Over the past 30 days, the price of RXRX has leaped by -29.95%. And in the last five days, it has fallen by -22.52%.
Recursion Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $12.36 on 02/18/25 and the lowest value was $5.60 on 03/31/25.
52-week price history of RXRX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Recursion Pharmaceuticals Inc’s current trading price is -57.44% away from its 52-week high, while its distance from the 52-week low is -6.05%. The stock’s price range during this period has varied between$5.60 and $12.36. The Recursion Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 8.82 million for the day, a figure considerably lower than their average daily volume of 23.01 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly decline of -31.32% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.11B.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 7.12, with a change in price of -1.12. Similarly, Recursion Pharmaceuticals Inc recorded 19,312,152 in trading volume during the last 100 days, posting a change of -17.50%.
RXRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.
RXRX Stock Stochastic Average
As of today, Recursion Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 1.26%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 5.14%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 6.65% and 11.52%, respectively.
